(S)-tert-butoxycarbonylamino-cyclohexyl-acetic acid cyclopentyl ester | 914604-31-2

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: (S)-tert-butoxycarbonylamino-cyclohexyl-acetic acid cyclopentyl ester
• 英文别名: cyclopentyl (2S)-[(tert-butoxycarbonyl)amino](cyclohexyl)acetate；cyclopentyl (2S)-2-cyclohexyl-2-[(2-methylpropan-2-yl)oxycarbonylamino]acetate
• CAS: 914604-31-2
• 化学式: C₁₈H₃₁NO₄
• 分子量: 325.448
• InChiKey: VPDXJTDXSSGIMS-HNNXBMFYSA-N

物化性质

• 沸点：
  440.2±28.0 °C(Predicted)
• 密度：
  1.07±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  4.5
• 重原子数：
  23
• 可旋转键数：
  7
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.89
• 拓扑面积：
  64.6
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  (S)-tert-butoxycarbonylamino-cyclohexyl-acetic acid cyclopentyl ester 在 盐酸 、 三乙酰氧基硼氢化钠 作用下， 以 1,4-二氧六环 、 二氯甲烷 、 1,2-二氯乙烷 为溶剂， 反应 27.0h， 生成 cyclopentyl (2S)-[(4-{[(tert-butoxycarbonyl)amino]methyl}benzyl)amino](cyclohexyl)acetate
  参考文献：
  名称：

  WO2008/40934

  摘要：

  公开号：
• 作为产物：
  描述：

  环戊醇 、 Boc-L-环己基甘氨酸 在 4-二甲氨基吡啶 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 以55%的产率得到(S)-tert-butoxycarbonylamino-cyclohexyl-acetic acid cyclopentyl ester
  参考文献：
  名称：

  [EN] INHIBITORS OF HSP90
  [FR] INHIBITEURS D'HSP90

  摘要：

  该发明提供了一种化合物，该化合物是(a) 公式(I)的吡咯吡嘧啶衍生物或其互变异构体，或者(b) 该化合物的药用可接受的盐、N-氧化物、水合物或溶剂化合物：公式(I)其中R1、R2、R3、R4和W如本文所定义。这些化合物在治疗由HSP90介导的疾病以及治疗炎症方面是有用的。

  公开号：

  WO2010043865A1

文献信息

• [EN] P38 MAP KINASE INHIBITORS<br/>[FR] INHIBITEURS DE LA MAP KINASE P38
  申请人：CHROMA THERAPEUTICS LTD

  公开号：WO2009060160A1

  公开（公告）日：2009-05-14

  Compounds of formula (I) are inhibitors of p38 MAP kinase, and are therefore of utility in the treatment of, inter alia, inflammatory conditions including rheumatoid arthritis and COPD: formula (I) wherein: G is -N= or -CH=; D is an optionally substituted divalent mono- or bi-cyclic aryl or heteroaryl radical having 5 - 13 ring members; R6 is hydrogen or optionally substituted C1-C3 alkyl; P represents hydrogen and U represents a radical of formula (IA); or U represents hydrogen and P represents a radical of formula -A-(CH2)z-X1-L1 -Y-NH-CHR1R2 wherein A represents an optionally substituted divalent mono- or bicyclic carbocyclic or heterocyclic radical having 5 - 13 ring members; z, Y, L1, and X1 are as defined in the specification; R1 is a carboxylic acid group (-COOH), or an ester group which is hydrolysable by one or more intracellular esterase enzymes to a carboxylic acid group; and R2 is the side chain of a natural or non-natural alpha amino acid.

  公式（I）的化合物是p38 MAP激酶的抑制剂，因此在治疗炎症性疾病包括类风湿性关节炎和COPD方面具有效用：公式（I）其中：G是-N =或-CH =; D是具有5-13个环成员的可选取代的二价单环或双环芳基或杂芳基基团; R6是氢或可选取代的C1-C3烷基; P代表氢，U代表公式（IA）的基团;或U代表氢，P代表公式-A-（CH2）z-X1-L1-Y-NH-CHR1R2的基团，其中A代表具有5-13个环成员的可选取代的二价单环或双环碳环或杂环基团; z，Y，L1和X1如规范中定义; R1是羧酸基（-COOH）或可由一个或多个细胞内酯酶酶水解为羧酸基的酯基;而R2是天然或非天然α氨基酸的侧链。
• ENZYME INHIBITORS
  申请人：Davidson Alan Hornsby

  公开号：US20140163042A1

  公开（公告）日：2014-06-12

  Compounds of formula (I) are inhibitors of histone deacetylase activity, and are useful in the treatment of, for example, cancers, wherein R 1 is a carboxylic acid group (—COOH), or an ester group which is hydrolysable by one or more intracellular carboxyesterase enzymes to a carboxylic acid group; R 2 is the side chain of a natural or non-natural alpha amino acid; Y is a bond, —C(═O), —S(═O) 2 —, —C(═O)O—, —C(O)NR 3 —, —C(═S)—NR 3 , —C(═NH)NR 3 or —S(═O) 2 NR 3 — wherein R 3 is hydrogen or optionally substituted C 1 -C 6 alkyl; L 1 is a divalent radical of formula -(Alk 1 ) m (Q) n (Alk 2 ) p - wherein m, n and p are independently 0 or 1, Q is (i) an optionally substituted divalent mono- or bicyclic carbocyclic or heterocyclic radical having 5-13 ring members, or (ii), in the case where both m and p are 0, a divalent radical of formula —X 2 -Q 1 - or -Q 1 -X 2 — wherein X 2 is —O—, S— or NR A — wherein R A is hydrogen or optionally substituted C 1 -C 3 alkyl, and Q 1 is an optionally substituted divalent mono- or bicyclic carbocyclic or heterocyclic radical having 5-13 ring members, Alk 1 and Alk 2 independently represent optionally substituted divalent C 3 -C 7 cycloalkyl radicals, or optionally substituted straight or branched, C 1 -C 6 alkylene, C 2 -C 6 alkenylene, or C 2 -C 6 alkynylene radicals which may optionally contain or terminate in an ether (—O—), thioether (—S—) or amino (—NR A —) link wherein R A is hydrogen or optionally substituted C 1 -C 3 alkyl; X 1 represents a bond; —C(═O); or —S(═O) 2 —; —NR 4 C(═O)—, —C(═O)NR 4 —, —NR 4 C(═O)NR 5 —, —NR 4 S(═O) 2 —, or —S(═O) 2 NR 4 — wherein R 4 and R 5 are independently hydrogen or optionally substituted C 1 -C 6 alkyl; z is 0 or 1; A represents an optionally substituted mono-, bi- or tri-cyclic carbocyclic or heterocyclic ring system wherein the radicals R 1 R 2 NH—Y-L 1 -X 1 -[CH 2 ] Z — and HONHCO-[LINKER]- are attached different ring atoms; and -[Linker]- represents a divalent linker radical linking a ring atom in A with the hydroxamic acid group CONIIOII, the length of the linker radical, from the terminal atom linked to the ring atom of A to the terminal atom linked to the hydroxamic acid group, is equivalent to that of an unbranched saturated hydrocarbon chain of from 3-10 carbon atoms.

  式(I)的化合物是组蛋白去乙酰化酶活性抑制剂，可用于治疗癌症等疾病，其中R1是羧酸基（-COOH）或可由一个或多个细胞内羧酸酯酶水解为羧酸基的酯基；R2是天然或非天然α氨基酸的侧链；Y是键，-C（=O），-S（=O）2-，-C（=O）O-，-C（=O）NR3-，-C（=S）-NR3，-C（=NH）NR3或-S（=O）2NR3-，其中R3是氢或可选取代的C1-C6烷基；L1是式-(Alk1)m(Q)n(Alk2)p-的二价基团，其中m、n和p独立地为0或1，Q是（i）一个可选取代的二价单环或双环碳环或杂环基团，具有5-13个环成员，或（ii）在m和p均为0的情况下，是式-Q1-X2-或-X2-Q1-的二价基团，其中X2是-O-，-S-或-NRA-，其中RA是氢或可选取代的C1-C3烷基，Q1是可选取代的二价单环或双环碳环或杂环基团，具有5-13个环成员，Alk1和Alk2独立地表示可选取代的二价C3-C7环烷基基团，或可选取代的直链或支链，C1-C6烷基，C2-C6烯基或C2-C6炔基基团，其可以可选地含有或终止于醚（-O-），硫醚（-S-）或氨基（-NRA-）链，其中RA是氢或可选取代的C1-C3烷基；X1表示键，-C（=O）或-S（=O）2-；-NR4C（=O）-，-C（=O）NR4-，-NR4C（=O）NR5-，-NR4S（=O）2-或-S（=O）2NR4-，其中R4和R5独立地为氢或可选取代的C1-C6烷基；z为0或1；A表示可选取代的单环、双环或三环碳环或杂环系统，其中基团R1R2NH-Y-L1-X1-[CH2]Z-和HONHCO-[LINKER]-附着在不同的环原子上；-[Linker]-表示将A中的一个环原子与羟酰胺酸基团CONIIOII连接的二价连接基团，连接基团的长度，从连接到A环原子的末端原子到连接到羟酸胺基团的末端原子，相当于从3-10个碳原子的直链饱和碳氢链的长度。
• HDAC INHIBITORS
  申请人：Davidson Alan Hornsby

  公开号：US20100010010A1

  公开（公告）日：2010-01-14

  Compounds of formula (I) inhibit HDAC activity, wherein A, B and D independently represent ═C— or ═N—; W is a divalent radical —CH═CH— or CH 2 CH 2 —; R 1 is a carboxylic acid group (—COOH), or an ester group which is hydrolysable by one or more intracellular carboxyesterase enzymes to a carboxylic acid group; R 2 is the side chain of a natural or non-natural alpha amino acid; z is 0 or 1; and Y, L 1 , and X 1 are as defined in the claims.

  公式（I）的化合物抑制HDAC活性，其中A、B和D分别表示═C—或═N—；W是二价基团—CH═CH—或CH2CH2—；R1是羧酸基（—COOH），或者是可被一个或多个细胞内羧酸酯酶水解为羧酸基的酯基团；R2是天然或非天然α氨基酸的侧链；z为0或1；Y、L1和X1如权利要求中所定义。
• THIAZOLE DERIVATIVES AS INHIBITORS OF P13 KINASE
  申请人：Moffat David Charles Festus

  公开号：US20100010057A1

  公开（公告）日：2010-01-14

  Compounds of formula (I) are inhibitors of P13 kinase activity, and useful in treatment of, inter alia, autoimmune, inflammatory and proliferative diseases: wherein: s is 0 or 1; U is hydrogen or halogen; X is —(C═O), an optionally substituted divalent phenylene, pyridinylene, pyrimidinylene, or pyrazinylene radical, or a bond; P is optionally substituted C 1 -C 6 alkyl and Z is —(CH 2 ) Z —X 1 -L 1 -NHCHR 1 R 2 ; or Z is optionally substituted C 1 -C 6 alkyl and P is —(CH 2 ) Z —X 1 -L 1 -NHCHR 1 R 2 ; R 1 is a carboxylic acid group (—COOH), or an ester group which is hydrolysable by one or more intracellular carboxylesterase enzymes to a carboxylic acid group; R 2 is the side chain of a natural or non-natural alpha amino acid; X 1 is (i) a bond; —NR 4 C(═O)NR 5 — or —NR 4 S(═O) 2 —; or except when X is —(C═O)— (ii) —C(═O)—, —S(═O) 2 —, or —S(═O) 2 NR 4 — wherein R 4 and R 5 are independently hydrogen or optionally substituted C 1 -C 6 alkyl; and z and L1 are as defined in the specification.

  化合物式(I)的复合物是P13激酶活性的抑制剂，并可用于治疗自身免疫性、炎症性和增殖性疾病，其中：s为0或1；U为氢或卤素；X为-(C═O)、一个可选取代的二价苯撑基、吡啶撑基、嘧啶撑基或吡嗪撑基基团，或一个键；P为可选取代的C1-C6烷基，Z为-(CH2)Z-X1-L1-NHCHR1R2；或Z为可选取代的C1-C6烷基，P为-(CH2)Z-X1-L1-NHCHR1R2；R1为羧酸基(—COOH)或一个酯基，该酯基可被一个或多个细胞内羧酸酯酶水解为羧酸基；R2为自然或非天然α-氨基酸的侧链；X1为(i)一个键；-NR4C(═O)NR5-或-NR4S(═O)2-；或除非X为-(C═O)- (ii) -C(═O)-、-S(═O)2-或-S(═O)2NR4-，其中R4和R5独立地为氢或可选取代的C1-C6烷基；z和L1如规范中定义。
• Enzyme Inhibitors
  申请人：Davidson Alan Hornsby

  公开号：US20090291978A1

  公开（公告）日：2009-11-26

  Compounds of formula (I) are inhibitors of histone deacetylase activity, and are useful in the treatment of, for example, cancers, wherein R 1 is a carboxylic acid group (—COOH), or an ester group which is hydrolysable by one or more intracellular carboxyesterase enzymes to a carboxylic acid group; R 2 is the side chain of a natural or non-natural alpha amino acid; Y is a bond, C(═O)—, —S(═O) 2 —, —C(—O)O—, —C(O)NR 3 —, —C(═S)—NR 3 , —C(═NH)NR 3 or —S(═O) 2 NR 3 — wherein R 3 is hydrogen or optionally substituted C 1 -C 6 alkyl; L is a divalent radical of formula -(Alk 1 ) m (O) n (Alk 2 ) p — wherein m, n and p are independently 0 or 1, Q is (i) an optionally substituted divalent mono- or bicyclic carbocyclic or heterocyclic radical having 5-13 ring members, or (ii), in the case where both m and p are 0, a divalent radical of formula —X 2 -Q 1 - or -Q 1 -X 2 — wherein X 2 is —O—, S— or NR A — wherein R A is hydrogen or optionally substituted C 1 -C 3 alkyl, and Q 1 is an optionally substituted divalent mono- or bicyclic carbocyclic or hetero-cyclic radical having 5-13 ring members, AIk 1 and AIk 2 independently represent optionally substituted divalent C 3 -C 7 cycloalkyl radicals, or optionally substituted straight or branched, C 1 -C 6 alkylene, C 2 -C 6 alkenylene, or C 2 -C 6 alkynylene radicals which may optionally contain or terminate in an ether (—O—), thioether (—S—) or amino (—NR A -) link wherein R A is hydrogen or optionally substituted C 1 -C 3 alkyl; X represents a bond; —C(═O); or —S(═O) 2 —; —NR 4 C(═O)—, —C(═O)NR 4 —, —NR 4 C(═O)NR 5 —, —NR 4 S(═O) 2 —, or —S(═O) 2 NR 4 — wherein R 4 and R 5 are independently hydrogen or optionally substituted C 1 -C 6 alkyl; z is 0 or 1; A represents an optionally substituted mono-, bi- or tri-cyclic carbocyclic or heterocyclic ring system wherein the radicals R 1 R 2 NH—Y-L 1 -X 1 —[CH 2 ] z — and HONHCO-[LINKER]- are attached different ring atoms; and -[Linker]- represents a divalent linker radical linking a ring atom in A with the hydroxamic acid group CONHOH, the length of the linker radical, from the terminal atom linked to the ring atom of A to the terminal atom linked to the hydroxamic acid group, is equivalent to that of an unbranched saturated hydrocarbon chain of from 3-10 carbon atoms.

  式(I)的化合物是组蛋白去乙酰化酶抑制剂，可用于治疗癌症等疾病，其中R1是羧酸基（-COOH）或一个可被一个或多个细胞内羧酸酯酶水解为羧酸基的酯基；R2是天然或非天然α氨基酸的侧链；Y是键，C（═O）—，—S（═O）2—，—C（—O）O—，—C（O）NR3—，—C（═S）—NR3，—C（═NH）NR3或—S（═O）2NR3—，其中R3是氢或可选择性取代的C1-C6烷基；L是式-(Alk1)m(O)n(Alk2)p-的二价基团，其中m、n和p分别独立为0或1；Q是（i）一个可选择性取代的二价单环或双环碳环或杂环基团，其具有5-13个环成员，或（ii）在m和p都为0的情况下，是式—X2-Q1-或-Q1-X2—的二价基团，其中X2是—O—，S—或NRA—，其中RA是氢或可选择性取代的C1-C3烷基，Q1是一个可选择性取代的二价单环或双环碳环或杂环基团，其具有5-13个环成员，Alk1和Alk2独立地表示可选择性取代的二价C3-C7环烷基基团，或可选择性取代的直链或支链C1-C6烷基、C2-C6烯基或C2-C6炔基基团，其可以选择性地包含或终止于醚（-O-）、硫醚（-S-）或氨基（-NRA-）链，其中RA是氢或可选择性取代的C1-C3烷基；X表示键，—C（═O）；或—S（═O）2—；—NR4C（═O）—，—C（═O）NR4—，—NR4C（═O）NR5—，—NR4S（═O）2—或—S（═O）2NR4—，其中R4和R5独立地为氢或可选择性取代的C1-C6烷基；z为0或1；A表示可选择性取代的单环、双环或三环碳环或杂环系统，其中基团R1R2NH—Y-L1-X1—[CH2]z—和HONHCO-[LINKER]-附着于不同的环原子上；-[Linker]-表示连接A中的一个环原子与羟酰胺酸基团CONHOH的二价连接基团，连接基团的长度，从连接到A环原子的末端原子到连接到羟酸胺基团的末端原子，相当于3-10个碳原子的直链饱和烃链的长度。